• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hemorrhagic stroke associated with essential thrombocythemia: Case report and literature review
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by the overproduction of circulating platelets in the peripheral blood, caused by the excessive proliferation of megakaryocytes in the bone marrow.1 Cerebrovascular events, mainly ischemic stroke, are one of the most serious complications in patients with ET, and the V617F mutation in the Janus kinase 2 (JAK2) gene is recognized as a thrombotic risk factor.2 Hemorrhagic stroke associated with ET is very infrequent, and the effect of mutation types on hemorrhagic stroke remains unclear.
Source: Journal of Stroke and Cerebrovascular Diseases - August 11, 2020 Category: Neurology Authors: Akihiko Momozaki, Jun Masuoka, Takashi Furukawa, Motofumi Koguchi, Hiroshi Ito, Fumitaka Yoshioka, Kohei Inoue, Atsushi Ogata, Yukiko Nakahara, Tatsuya Abe Tags: Case Report Source Type: research

A Nationwide Analysis of Outcomes of Stroke in Hospitalized Patients with Essential Thrombocythemia: 2006 to 2014
Conclusions:Patients with ET who are hospitalized with stroke have significantly worse outcomes. This study demonstrated that a statistically significant difference exists among different age groups of patients with ET and stoke who died during hospitalization when stratification is made using age groups and Charlson Score. This study may serve as an initial point to include new risk factors for further risk stratification. Early identification of patients at higher risk may reduce the incidence and decrease the morbidity of stroke in patients with ET.DisclosuresKota: BMS: Honoraria; Novartis: Honoraria; Xcenda: Honoraria;...
Source: Blood - November 21, 2018 Category: Hematology Authors: Ajebo, G., Badin, K., Forehand, W., Guddati, A. K., Kota, V. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster III Source Type: research

Direct Oral Anticoagulants in Patients with Myeloproliferative Neoplasms: A Single Institution Retrospective Study
Discussion: Our limited data suggests that use of DOACs in patients with MPN is feasible with an acceptable balance between risk of hemorrhage and recurrent thrombosis. Additional data on long term outcomes of DOACs in MPNs are needed.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Deloughery, E. P., McBane, R. D., Ashrani, A. A., Tefferi, A., Slusser, J. P., Pruthi, R. K. Tags: 332. Antithrombotic Therapy Source Type: research

Cerebral Hemorrhage of a 50-Year-Old Female Patient with Polycythemia Vera
Polycythemia vera is a chronic myeloproliferative neoplasm, which is primarily characterized by elevated erythrocyte count with the risk of thrombosis, hemorrhage, and vasomotor symptoms. More common reported about bleeding events are gastrointestinal, mucosal, and cutaneous bleeding. Spontaneous cerebral hemorrhage/bleeding is seldom reported. Here, we report the case of a 50-year-old female with polycythemia vera who developed a spontaneous cerebral hemorrhage. She improved significantly after hydroxyurea agent and red cell apheresis, and the hematocrit decreased from 74% to 40%.
Source: Journal of Stroke and Cerebrovascular Diseases - May 20, 2019 Category: Neurology Authors: Lei Chen, Han Xiao, Zhiping Hu Tags: Case Report Source Type: research

Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer
AbstractPurpose of ReviewThis review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).Recent FindingsThe MPN natural history is driven by uncontrolled clonal myeloproliferation sustained by acquired somatic mutations in driver (JAK2, CALR, and MPL) and non-driver genes, involving epigenetic (e.g., TET2, DNMT3A) regulators, chromatin regulator genes (e.g., ASXL1, EZH2), and splicing machinery ...
Source: Current Hematologic Malignancy Reports - May 24, 2023 Category: Hematology Source Type: research